These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8602114)

  • 1. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
    Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
    Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
    Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.
    Knoll J; Miklya I
    Life Sci; 1995; 56(8):611-20. PubMed ID: 7869839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
    Miklya I; Knoll B; Knoll J
    Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain.
    Knoll J; Miklya I; Knoll B; Markó R; Rácz D
    Life Sci; 1996; 58(23):2101-14. PubMed ID: 8649195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant.
    Knoll J; Knoll B; Török Z; Timár J; Yasar S
    Arch Int Pharmacodyn Ther; 1992; 316():5-29. PubMed ID: 1356324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
    Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats.
    Miklya I; Knoll B; Knoll J
    Life Sci; 2003 May; 72(25):2923-30. PubMed ID: 12697275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers.
    Knoll J; Knoll B; Miklya I
    Life Sci; 1996; 58(11):945-52. PubMed ID: 8786700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
    Miklya I
    Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
    Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
    Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual performance and longevity.
    Knoll J
    Exp Gerontol; 1997; 32(4-5):539-52. PubMed ID: 9315455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
    Miklya I
    Pharmacol Rep; 2014 Jun; 66(3):453-8. PubMed ID: 24905523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.